Table 1.
Subject characteristics at baseline visit. Data are n (%) unless otherwise indicated.
| Characteristic | GENISOS Cohort | Control Subjects |
|---|---|---|
| Sex, female | 221 (83) | 78 (80) |
| Age at the time of first study visit, mean (SD) yrs |
48.6 (13.5) | 48 (12.7) |
| Ethnicity | ||
| White | 125 (47) | 48 (49) |
| African American | 54 (20) | 17 (18) |
| Latino | 77 (29) | 27 (29) |
| Asian | 10 (4) | 5 (5) |
| Diffuse cutaneous involvement | 156 (59) | |
| Disease duration 1, mean (SD)* | 2.5 (1.6) | |
| Disease duration 2, mean (SD)** | 4.5 (5.4) | |
| ACA | 32 (12) | |
| ATA | 49 (18) | |
| ARA | 61 (23) | |
| Forced vital capacty percentage predicted | ||
| > 80 | 132 (58.1) | |
| 50 to 80 | 81 (35.7) | |
| < 50 | 14 (6.2) | |
| Treatment with immunosuppressive agents |
82 (32) | |
*
Disease duration 1 was calculated from the onset of the first non-Raynaud syndrome.
**
Disease duration 2 was calculated from the onset of the first symptom attributable to systemic sclerosis including Raynaud. ACA: anticentromere antibodies; ATA: antitopoisomerase antibodies; ARA: anti-RNA polymerase III antibodies.